Literature DB >> 3494528

Variation in susceptibility of Balb/c mice to coxsackievirus group B type 3-induced myocarditis with age.

D Lyden, J Olszewski, S Huber.   

Abstract

The severity of cardiac lesions in coxsackievirus group B, type 3 (CVB3)-infected Balb/c mice depends upon both the age and the sex of the animal at the time of viral inoculation. Suckling animals (1-3 weeks old) of either sex develop few cardiac lesions. Thereafter, males rapidly demonstrate increasing disease susceptibility peaking at 16-18 weeks old and then decreasing susceptibility from 20 to 40 weeks of age. Female susceptibility increases much more gradually and myocarditis in this sex never reaches maximal levels as seen in males. Increased susceptibility correlates with virus concentrations in the heart and anti-CVB3 titers in the serum. Cardiac injury is dependent on functional T lymphocytes since treatment of the animals with rabbit anti-mouse thymocyte serum abrogates inflammation and myocyte necrosis. Sex-associated steroid hormones influence both virus concentrations and immune responses in mice and are probably responsible for variations in disease susceptibility throughout the animal's life.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494528     DOI: 10.1016/0008-8749(87)90081-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

Review 1.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Characteristics of Clinically Diagnosed Pediatric Myocarditis in a Contemporary Multi-Center Cohort.

Authors:  Ryan J Butts; Gerard J Boyle; Shriprasad R Deshpande; Katheryn Gambetta; Kenneth R Knecht; Carolina A Prada-Ruiz; Marc E Richmond; Shawn C West; Ashwin K Lal
Journal:  Pediatr Cardiol       Date:  2017-05-23       Impact factor: 1.655

3.  Sex-Dependent Intestinal Replication of an Enteric Virus.

Authors:  Christopher M Robinson; Yao Wang; Julie K Pfeiffer
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  Hormonal regulation of CD4(+) T-cell responses in coxsackievirus B3-induced myocarditis in mice.

Authors:  S A Huber; J Kupperman; M K Newell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.

Authors:  H Zhang; G E Yousef; X Ouyang; L C Archard
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

6.  Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d.

Authors:  Sally A Huber
Journal:  Med Microbiol Immunol       Date:  2004-04-24       Impact factor: 3.402

7.  Autoimmune myocarditis, valvulitis, and cardiomyopathy.

Authors:  Jennifer M Myers; DeLisa Fairweather; Sally A Huber; Madeleine W Cunningham
Journal:  Curr Protoc Immunol       Date:  2013

Review 8.  Clinical and experimental aspects of viral myocarditis.

Authors:  K Leslie; R Blay; C Haisch; A Lodge; A Weller; S Huber
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

9.  Presumptive myocarditis with ST-Elevation myocardial infarction presentation in young males as a new syndrome. Clinical significance and long term follow up.

Authors:  Marcello Costantini; Giuseppe Oreto; Alberto Albanese; Anna Ranieri; Giovanni De Fabrizio; Iovanni Sticchi; Antonio Lauretti; Sergio Capone; Cristina Tritto; Claudio Fachechi; Realino Renna; Antonio Montinaro; Eugenio Picano
Journal:  Cardiovasc Ultrasound       Date:  2011-01-18       Impact factor: 2.062

10.  Chromosome y regulates survival following murine coxsackievirus b3 infection.

Authors:  Laure K Case; Leon Toussaint; Mohamad Moussawi; Brian Roberts; Naresha Saligrama; Laurent Brossay; Sally A Huber; Cory Teuscher
Journal:  G3 (Bethesda)       Date:  2012-01-01       Impact factor: 3.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.